Patents by Inventor Glenn Pierce

Glenn Pierce has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Methods of reducing immunogenicity against factor VIII in individuals undergoing factor VIII therapy
    Patent number: 12371747
    Abstract: The present disclosure provides methods of administering chimeric and hybrid Factor VIII (FVIII) polypeptides comprising FVIII and Fc to subjects at risk of developing inhibitory FVIII immune responses, including anti-FVIII antibodies and/or cell-mediated immunity. The administration is sufficient to promote coagulation and to induce immune tolerance to FVIII. The chimeric polypeptide can comprise full-length FVIII or a FVIII polypeptide containing a deletion, e.g., a full or partial deletion of the B domain.
    Type: Grant
    Filed: February 25, 2022
    Date of Patent: July 29, 2025
    Assignees: BIOVERATIV THERAPEUTICS INC., PUGET SOUND BLOOD CENTER
    Inventors: Haiyan Jiang, Tongyao Liu, Sriram Krishnamoorthy, Neil Josephson, Glenn Pierce
  • Factor VIII chimeric and hybrid polypeptides, and methods of use thereof
    Patent number: 12186375
    Abstract: The present invention provides methods of administering Factor VIII (processed FVIII, single chain FVIII, or a combination thereof); methods of administering chimeric and hybrid polypeptides comprising Factor VIII; chimeric and hybrid polypeptides comprising Factor VIII; polynucleotides encoding such chimeric and hybrid polypeptides; cells comprising such polynucleotides; and methods of producing such chimeric and hybrid polypeptides using such cells.
    Type: Grant
    Filed: December 4, 2020
    Date of Patent: January 7, 2025
    Assignee: BIOVERATIV THERAPEUTICS INC.
    Inventors: Jennifer A. Dumont, Susan Low, Alan J. Bitonti, Glenn Pierce, Alvin Luk, Haiyan Jiang, Byron McKinney, Matt Ottmer, Jurg Sommer, Karen Nugent, Lian Li, Robert T. Peters
  • Assays to monitor bleeding disorders
    Patent number: 11747351
    Abstract: The present invention provides methods of dosing Factor VIII or Factor IX chimeric and hybrid polypeptides. The present invention further provides high-sensitivity methods of quantifying an amount of activated FIX protein in a test sample.
    Type: Grant
    Filed: April 14, 2020
    Date of Patent: September 5, 2023
    Assignee: BIOVERATIV THERAPEUTICS INC.
    Inventors: Jurg Sommer, Haiyan Jiang, Xin Zhang, Buyue Yang, Glenn Pierce
  • Methods of reducing immunogenicity against factor VIII in individuals undergoing factor VIII therapy
    Patent number: 11286528
    Abstract: The present disclosure provides methods of administering chimeric and hybrid Factor VIII (FVIII) polypeptides comprising FVIII and Fc to subjects at risk of developing inhibitory FVIII immune responses, including anti-FVIII antibodies and/or cell-mediated immunity. The administration is sufficient to promote coagulation and to induce immune tolerance to FVIII. The chimeric polypeptide can comprise full-length FVIII or a FVIII polypeptide containing a deletion, e.g., a full or partial deletion of the B domain.
    Type: Grant
    Filed: January 11, 2019
    Date of Patent: March 29, 2022
    Assignees: BIOVERATIV THERAPEUTICS INC., PUGET SOUND BLOOD CENTER
    Inventors: Haiyan Jiang, Tongyao Liu, Sriram Krishnamoorthy, Neil Josephson, Glenn Pierce
  • Factor VIII-FC chimeric and hybrid polypeptides, and methods of use thereof
    Patent number: 11266720
    Abstract: The present invention provides methods of administering Factor VIII; methods of administering chimeric and hybrid polypeptides comprising Factor VIII; chimeric and hybrid polypeptides comprising Factor VIII; polynucleotides encoding such chimeric and hybrid polypeptides; cells comprising such polynucleotides; and methods of producing such chimeric and hybrid polypeptides using such cells.
    Type: Grant
    Filed: February 7, 2019
    Date of Patent: March 8, 2022
    Assignee: BIOVERATIV THERAPEUTICS INC.
    Inventors: Jennifer A. Dumont, Susan Low, Alan J. Bitonti, Glenn Pierce, Alvin Luk, Haiyan Jiang, Byron McKinney, Matt Ottmer, Jurg Sommer, Karen Nugent, Lian Li, Robert Peters
  • Methods of using FIX polypeptides
    Patent number: 11225650
    Abstract: The present invention provides methods of administering long-acting Factor IX; methods of administering long-acting, chimeric and hybrid polypeptides comprising Factor IX; and methods of producing such chimeric and hybrid polypeptides using cells.
    Type: Grant
    Filed: June 9, 2017
    Date of Patent: January 18, 2022
    Assignee: Bioverativ Therapeutics Inc.
    Inventors: Glenn Pierce, Samantha Truex, Robert T. Peters, Haiyan Jiang, Mark Brader
  • Methods of using FIX polypeptides
    Patent number: 11193116
    Abstract: The present invention provides methods of administering long-acting Factor IX; methods of administering long-acting, chimeric and hybrid polypeptides comprising Factor IX; and methods of producing such chimeric and hybrid polypeptides using cells.
    Type: Grant
    Filed: June 9, 2017
    Date of Patent: December 7, 2021
    Assignee: Bioverativ Therapeutics Inc.
    Inventors: Glenn Pierce, Samantha Truex, Robert T. Peters, Haiyan Jiang, Mark Brader
  • Factor IX polypeptides and methods of use thereof
    Patent number: 10898554
    Abstract: The present invention provides methods of administering Factor IX; methods of administering chimeric and hybrid polypeptides comprising Factor IX; polynucleotides encoding such chimeric and hybrid polypeptides; cells comprising such polynucleotides; and methods of producing such chimeric and hybrid polypeptides using such cells.
    Type: Grant
    Filed: September 25, 2020
    Date of Patent: January 26, 2021
    Assignee: BIOVERATIV THERAPEUTICS INC.
    Inventors: Glenn Pierce, Samantha Truex, Robert T. Peters, Haiyan Jiang
  • Factor VIII chimeric and hybrid polypeptides, and methods of use thereof
    Patent number: 10881742
    Abstract: The present invention provides methods of administering Factor VIII (processed FVIII, single chain FVIII, or a combination thereof); methods of administering chimeric and hybrid polypeptides comprising Factor VIII; chimeric and hybrid polypeptides comprising Factor VIII; polynucleotides encoding such chimeric and hybrid polypeptides; cells comprising such polynucleotides; and methods of producing such chimeric and hybrid polypeptides using such cells.
    Type: Grant
    Filed: May 29, 2018
    Date of Patent: January 5, 2021
    Assignee: Bioverativ Therapeutics Inc.
    Inventors: Jennifer A. Dumont, Susan Low, Alan J. Bitonti, Glenn Pierce, Alvin Luk, Haiyan Jiang, Byron McKinney, Matt Ottmer, Jurg Sommer, Karen Nugent, Lian Li, Robert T. Peters
  • Assays to monitor bleeding disorders
    Patent number: 10656167
    Abstract: The present invention provides methods of dosing Factor VIII or Factor IX chimeric and hybrid polypeptides. The present invention further provides high-sensitivity methods of quantifying an amount of activated FIX protein in a test sample.
    Type: Grant
    Filed: July 25, 2012
    Date of Patent: May 19, 2020
    Assignee: BIOVERATIV THERAPEUTICS INC.
    Inventors: Jurg Sommer, Haiyan Jiang, Xin Zhang, Buyue Yang, Glenn Pierce
  • Factor IX polypeptides and methods of use thereof
    Patent number: 10568943
    Abstract: The present invention provides methods of administering Factor IX; methods of administering chimeric and hybrid polypeptides comprising Factor IX; polynucleotides encoding such chimeric and hybrid polypeptides; cells comprising such polynucleotides; and methods of producing such chimeric and hybrid polypeptides using such cells.
    Type: Grant
    Filed: February 8, 2019
    Date of Patent: February 25, 2020
    Assignee: BIOVERATIV THERAPEUTICS INC.
    Inventors: Glenn Pierce, Samantha Truex, Robert T. Peters, Haiyan Jiang
  • Factor IX polypeptides and methods of use thereof
    Patent number: 10561714
    Abstract: The present invention provides methods of administering Factor IX; methods of administering chimeric and hybrid polypeptides comprising Factor IX; polynucleotides encoding such chimeric and hybrid polypeptides; cells comprising such polynucleotides; and methods of producing such chimeric and hybrid polypeptides using such cells.
    Type: Grant
    Filed: February 6, 2018
    Date of Patent: February 18, 2020
    Assignee: Bioverativ Therapeutics Inc.
    Inventors: Glenn Pierce, Samantha Truex, Robert T. Peters, Haiyan Jiang
  • Factor IX polypeptides and methods of use thereof
    Patent number: 10548954
    Abstract: The present invention provides methods of administering Factor IX; methods of administering chimeric and hybrid polypeptides comprising Factor IX; polynucleotides encoding such chimeric and hybrid polypeptides; cells comprising such polynucleotides; and methods of producing such chimeric and hybrid polypeptides using such cells.
    Type: Grant
    Filed: February 8, 2019
    Date of Patent: February 4, 2020
    Assignee: BIOVERATIV THERAPEUTICS INC.
    Inventors: Glenn Pierce, Samantha Truex, Robert T. Peters, Haiyan Jiang
  • METHODS OF REDUCING IMMUNOGENICITY AGAINST FACTOR VIII IN INDIVIDUALS UNDERGOING FACTOR VIII THERAPY
    Publication number: 20190241960
    Abstract: The present disclosure provides methods of administering chimeric and hybrid Factor VIII (FVIII) polypeptides comprising FVIII and Fc to subjects at risk of developing inhibitory FVIII immune responses, including anti-FVIII antibodies and/or cell-mediated immunity. The administration is sufficient to promote coagulation and to induce immune tolerance to FVIII. The chimeric polypeptide can comprise full-length FVIII or a FVIII polypeptide containing a deletion, e.g., a full or partial deletion of the B domain.
    Type: Application
    Filed: January 11, 2019
    Publication date: August 8, 2019
    Inventors: Haiyan Jiang, Tongyao Liu, Sriram Krishnamoorthy, Neil Josephson, Glenn Pierce
  • FACTOR IX POLYPEPTIDES AND METHODS OF USE THEREOF
    Publication number: 20190192640
    Abstract: The present invention provides methods of administering Factor IX; methods of administering chimeric and hybrid polypeptides comprising Factor IX; polynucleotides encoding such chimeric and hybrid polypeptides; cells comprising such polynucleotides; and methods of producing such chimeric and hybrid polypeptides using such cells.
    Type: Application
    Filed: February 8, 2019
    Publication date: June 27, 2019
    Inventors: Glenn Pierce, Samantha Truex, Robert T. Peters, Haiyan Jiang
  • FACTOR IX POLYPEPTIDES AND METHODS OF USE THEREOF
    Publication number: 20190192641
    Abstract: The present invention provides methods of administering Factor IX; methods of administering chimeric and hybrid polypeptides comprising Factor IX; polynucleotides encoding such chimeric and hybrid polypeptides; cells comprising such polynucleotides; and methods of producing such chimeric and hybrid polypeptides using such cells.
    Type: Application
    Filed: February 8, 2019
    Publication date: June 27, 2019
    Inventors: Glenn Pierce, Samantha Truex, Robert T. Peters, Haiyan Jiang
  • Methods of reducing immunogenicity against factor VIII in individuals undergoing factor VIII therapy
    Patent number: 10221455
    Abstract: The present disclosure provides methods of administering chimeric and hybrid Factor VIII (FVIII) polypeptides comprising FVIII and Fc to subjects at risk of developing inhibitory FVIII immune responses, including anti-FVIII antibodies and/or cell-mediated immunity. The administration is sufficient to promote coagulation and to induce immune tolerance to FVIII. The chimeric polypeptide can comprise full-length FVIII or a FVIII polypeptide containing a deletion, e.g., a full or partial deletion of the B domain.
    Type: Grant
    Filed: January 12, 2013
    Date of Patent: March 5, 2019
    Assignees: BIOVERATIV THERAPEUTICS INC., PUGET SOUND BLOOD CENTER
    Inventors: Haiyan Jiang, Tongyao Liu, Sriram Krishnamoorthy, Neil Josephson, Glenn Pierce
  • Targeted coagulation factors and method of using the same
    Patent number: 10035840
    Abstract: Targeted coagulation factors comprising a coagulation factor linked with at least one domain that specifically binds to a membrane protein on a blood cell is provided. The disclosed targeted coagulation factors increase the efficiency of coagulation factors and prolong their duration of action and thus, are an improvement for the treatment of hematological diseases such as hemophilia A.
    Type: Grant
    Filed: July 28, 2016
    Date of Patent: July 31, 2018
    Assignee: Bayer HealthCare LLC
    Inventors: Richard Feldman, Ji-Yun Kim, Haiyan Jiang, Kirk McLean, Junliang Pan, Glenn Pierce, James Wu, Xiao-Yan Zhao
  • Factor VIII chimeric and hybrid polypeptides, and methods of use thereof
    Patent number: 10010622
    Abstract: The present invention provides methods of administering Factor VIII (processed FVIII, single chain FVIII, or a combination thereof); methods of administering chimeric and hybrid polypeptides comprising Factor VIII; chimeric and hybrid polypeptides comprising Factor VIII; polynucleotides encoding such chimeric and hybrid polypeptides; cells comprising such polynucleotides; and methods of producing such chimeric and hybrid polypeptides using such cells.
    Type: Grant
    Filed: July 6, 2012
    Date of Patent: July 3, 2018
    Assignee: Bioverativ Therapeutics Inc.
    Inventors: Jennifer A. Dumont, Susan Low, Alan J. Bitoni, Glenn Pierce, Alvin Luk, Haiyan Jiang, Byron McKinney, Matt Ottmer, Jurg Sommer, Karen Nugent, Lian Li, Robert Peters
  • Factor IX polypeptides and methods of use thereof
    Patent number: 9867873
    Abstract: The present invention provides methods of administering Factor IX; methods of administering chimeric and hybrid polypeptides comprising Factor IX; polynucleotides encoding such chimeric and hybrid polypeptides; cells comprising such polynucleotides; and methods of producing such chimeric and hybrid polypeptides using such cells.
    Type: Grant
    Filed: December 29, 2015
    Date of Patent: January 16, 2018
    Assignee: BIOVERATIV THERAPEUTICS INC.
    Inventors: Glenn Pierce, Samantha Truex, Robert T. Peters, Haiyan Jiang